{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:42:30Z","timestamp":1793065350327,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National du Cancer","doi-asserted-by":"publisher","award":["INCa-DGOS-INSERM_12554"],"award-info":[{"award-number":["INCa-DGOS-INSERM_12554"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","award":["ANR-23-IAHU-0006"],"award-info":[{"award-number":["ANR-23-IAHU-0006"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.annonc.2025.11.002","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:51:18Z","timestamp":1763639478000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"L.","family":"Cabel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3251-4060","authenticated-orcid":false,"given":"F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"de la Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Hardy-Bessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-9165","authenticated-orcid":false,"given":"S.","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pradines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Callens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"F.C.","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.annonc.2025.11.002_bib1","first-page":"1244","article-title":"An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer","volume":"57","author":"Zhang","year":"1997","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2025.11.002_bib2","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.annonc.2025.11.002_bib3","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.annonc.2025.11.002_bib4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.annonc.2025.11.002_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","article-title":"Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations","volume":"33","author":"Jeselsohn","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2025.11.002_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13058-018-0968-0","article-title":"Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients","volume":"20","author":"Allouchery","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2025.11.002_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2019.188315","article-title":"The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: a systematic review and meta-analysis of randomized and non-randomized trials","volume":"1872","author":"Najim","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.11.002_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","article-title":"Activating ESR1 mutations differentially affect the efficacy of ER antagonists","volume":"7","author":"Toy","year":"2017","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.annonc.2025.11.002_bib9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2025.11.002_bib10","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/acs.analchem.2c00446","article-title":"Real-time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: feasibility and cross-validation with NGS","volume":"94","author":"Callens","year":"2022","journal-title":"Anal Chem"},{"issue":"3","key":"10.1016\/j.annonc.2025.11.002_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055821","volume":"12","author":"Berger","year":"2022","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.annonc.2025.11.002_bib12","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/s41388-020-1174-y","article-title":"A single droplet digital PCR for ESR1 activating mutations detection in plasma","volume":"39","author":"Jeannot","year":"2020","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.annonc.2025.11.002_bib13","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.11.002_bib14","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","article-title":"Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial","volume":"7","author":"Llombart-Cussac","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7404","key":"10.1016\/j.annonc.2025.11.002_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2025.11.002_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.406","article-title":"304P ESR1 mutations and outcomes in BRCA1\/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial","volume":"31","author":"Frenel","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2025.11.002_bib17","first-page":"GS3","article-title":"Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial","volume":"83","author":"Oliveira","year":"2023","journal-title":"Cancer Res"},{"issue":"28","key":"10.1016\/j.annonc.2025.11.002_bib18","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.11.002_bib19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"10063","key":"10.1016\/j.annonc.2025.11.002_bib20","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.annonc.2025.11.002_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342506260X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342506260X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:48:00Z","timestamp":1773946080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342506260X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S092375342506260X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.11.002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}